Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

The relationship between in vivo antiviral activity and pharmacokinetic parameters of peramivir in influenza virus infection model in mice.

Kodama M, Yoshida R, Hasegawa T, Izawa M, Kitano M, Baba K, Noshi T, Seki T, Okazaki K, Tsuji M, Kanazu T, Kamimori H, Homma T, Kobayashi M, Sakoda Y, Kida H, Sato A, Yamano Y.

Antiviral Res. 2014 Sep;109:110-5. doi: 10.1016/j.antiviral.2014.06.016. Epub 2014 Jul 2.

PMID:
24997412
2.

A single intramuscular injection of neuraminidase inhibitor peramivir demonstrates antiviral activity against novel pandemic A/California/04/2009 (H1N1) influenza virus infection in mice.

Bantia S, Kellogg D, Parker C, Upshaw R, Ilyushina NA, Babu YS.

Antiviral Res. 2011 Apr;90(1):17-21. doi: 10.1016/j.antiviral.2011.02.001. Epub 2011 Feb 21.

PMID:
21316393
3.

Influenza viral load and peramivir kinetics after single administration and proposal of regimens for peramivir administration against resistant variants.

Sato M, Ito M, Suzuki S, Sakuma H, Takeyama A, Oda S, Watanabe M, Hashimoto K, Miyazaki K, Kawasaki Y, Hosoya M.

Antimicrob Agents Chemother. 2015 Mar;59(3):1643-9. doi: 10.1128/AAC.04263-14. Epub 2014 Dec 29.

4.

Efficacy, safety, and pharmacokinetics of intravenous peramivir in children with 2009 pandemic H1N1 influenza A virus infection.

Sugaya N, Kohno S, Ishibashi T, Wajima T, Takahashi T.

Antimicrob Agents Chemother. 2012 Jan;56(1):369-77. doi: 10.1128/AAC.00132-11. Epub 2011 Oct 24.

5.

Peramivir pharmacokinetics in a patient receiving continuous veno-venous hemodiafiltration during the 2009 H1N1 influenza A pandemic.

Bentley ML, Hollistera AS, Hansenb AC, Smith JA, Cain JS.

Int J Clin Pharmacol Ther. 2014 Dec;52(12):1105-11. doi: 10.5414/CP202161.

PMID:
25345428
6.

Combinations of favipiravir and peramivir for the treatment of pandemic influenza A/California/04/2009 (H1N1) virus infections in mice.

Tarbet EB, Maekawa M, Furuta Y, Babu YS, Morrey JD, Smee DF.

Antiviral Res. 2012 Apr;94(1):103-10. doi: 10.1016/j.antiviral.2012.03.001. Epub 2012 Mar 10.

7.

Peramivir clearance in continuous renal replacement therapy.

Thomas B, Hollister AS, Muczynski KA.

Hemodial Int. 2010 Jul;14(3):339-40. doi: 10.1111/j.1542-4758.2010.00451.x. Epub 2010 May 18. No abstract available.

PMID:
20491974
8.

Intravenous peramivir inhibits viral replication, and leads to bacterial clearance and prevention of mortality during murine bacterial co-infection caused by influenza A(H1N1)pdm09 virus and Streptococcus pneumoniae.

Onishi M, Kitano M, Taniguchi K, Homma T, Kobayashi M, Yoshinaga T, Naito A, Sato A.

Antiviral Res. 2015 May;117:52-9. doi: 10.1016/j.antiviral.2015.02.012. Epub 2015 Mar 6.

PMID:
25752738
9.

Peramivir pharmacokinetics in two critically ill adults with 2009 H1N1 influenza A concurrently receiving continuous renal replacement therapy.

Bazan JA, Bauer KA, Hollister AS, Shidham G, Firstenberg MS, Reed EE, Mangino JE, Goff DA.

Pharmacotherapy. 2010 Oct;30(10):1016-20. doi: 10.1592/phco.30.10.1016.

PMID:
20874039
10.

Clinical experience in adults and children treated with intravenous peramivir for 2009 influenza A (H1N1) under an Emergency IND program in the United States.

Hernandez JE, Adiga R, Armstrong R, Bazan J, Bonilla H, Bradley J, Dretler R, Ison MG, Mangino JE, Maroushek S, Shetty AK, Wald A, Ziebold C, Elder J, Hollister AS, Sheridan W; eIND Peramivir Investigators.

Clin Infect Dis. 2011 Mar 15;52(6):695-706. doi: 10.1093/cid/cir001.

11.

Peramivir for the treatment of influenza.

Shetty AK, Peek LA.

Expert Rev Anti Infect Ther. 2012 Feb;10(2):123-43. doi: 10.1586/eri.11.174.

PMID:
22339187
13.

Intramuscularly administered neuraminidase inhibitor peramivir is effective against lethal H5N1 influenza virus in mice.

Boltz DA, Ilyushina NA, Arnold CS, Babu YS, Webster RG, Govorkova EA.

Antiviral Res. 2008 Nov;80(2):150-7. doi: 10.1016/j.antiviral.2008.05.012. Epub 2008 Jun 23.

14.

Efficacy of a single intravenous administration of laninamivir (an active metabolite of laninamivir octanoate) in an influenza virus infection mouse model.

Kakuta M, Kubo S, Tanaka M, Tobiume S, Tomozawa T, Yamashita M.

Antiviral Res. 2013 Oct;100(1):190-5. doi: 10.1016/j.antiviral.2013.08.004. Epub 2013 Aug 15.

PMID:
23954190
15.

Intravenous peramivir for treatment of influenza A and B virus infection in high-risk patients.

Kohno S, Kida H, Mizuguchi M, Hirotsu N, Ishida T, Kadota J, Shimada J; S-021812 Clinical Study Group.

Antimicrob Agents Chemother. 2011 Jun;55(6):2803-12. doi: 10.1128/AAC.01718-10. Epub 2011 Apr 4.

16.

Anti-influenza virus activity of peramivir in mice with single intramuscular injection.

Bantia S, Arnold CS, Parker CD, Upshaw R, Chand P.

Antiviral Res. 2006 Jan;69(1):39-45. Epub 2005 Nov 21.

PMID:
16325932
17.

The role of clinical pharmacology in supporting the emergency use authorization of an unapproved anti-influenza drug, peramivir.

Arya V, Carter WW, Robertson SM.

Clin Pharmacol Ther. 2010 Nov;88(5):587-9. doi: 10.1038/clpt.2010.187.

PMID:
20959843
18.

Pharmacokinetic Properties of Peramivir After Single and Multiple Intravenous Infusions in Healthy Chinese Volunteers.

Zhang M, Wang ZZ, Ni XJ, Li LZ, Zhang YF, Lu HY, Peng H, Huang WC, Shen LF, Xiong LH, Shang DW, Wen YG.

Clin Drug Investig. 2016 Sep;36(9):705-711. doi: 10.1007/s40261-016-0417-8.

PMID:
27317305
19.

Absence of pharmacokinetic interaction between intravenous peramivir and oral oseltamivir or rimantadine in humans.

Atiee G, Lasseter K, Baughman S, McCullough A, Collis P, Hollister A, Hernandez J.

J Clin Pharmacol. 2012 Sep;52(9):1410-9. doi: 10.1177/0091270011414574. Epub 2011 Sep 29.

PMID:
21960669
20.

Peramivir (BCX-1812, RWJ-270201): potential new therapy for influenza.

Sidwell RW, Smee DF.

Expert Opin Investig Drugs. 2002 Jun;11(6):859-69. Review.

PMID:
12036429

Supplemental Content

Support Center